Acid-cleavable thiomaleamic acid linker for homogeneous antibody–drug conjugation
Open Access
- 5 August 2013
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Chemical Communications
- Vol. 49 (74) , 8187-8189
Abstract
In this communication we describe a novel acid-cleavable linker strategy for antibody–drug conjugation. Functional disulfide bridging of the single interchain disulfide bond of a trastuzumab Fab fragment yields a homogeneous antibody–drug conjugate bearing a thiomaleamic acid linker. This linker is stable at physiological pH and temperature, but quantitatively cleaves at lysosomal pH to release the drug payload.Keywords
This publication has 27 references indexed in Scilit:
- A mild synthesis of N-functionalised bromomaleimides, thiomaleimides and bromopyridazinedionesTetrahedron Letters, 2013
- Homogeneous antibody fragment conjugation by disulfide bridging introduces ‘spinostics’Scientific Reports, 2013
- Marketed therapeutic antibodies compendiummAbs, 2012
- Investigational antibody drug conjugates for solid tumorsExpert Opinion on Investigational Drugs, 2011
- Tunable reagents for multi-functional bioconjugation: reversible or permanent chemical modification of proteins and peptides by control of maleimide hydrolysisChemical Communications, 2011
- In Situ Maleimide Bridging of Disulfides and a New Approach to Protein PEGylationBioconjugate Chemistry, 2011
- Protein Modification, Bioconjugation, and Disulfide Bridging Using BromomaleimidesJournal of the American Chemical Society, 2010
- Therapeutic antibodies: successes, limitations and hopes for the futureBritish Journal of Pharmacology, 2009
- Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic indexNature Biotechnology, 2008
- Dynamic PolyConjugates for targeted in vivo delivery of siRNA to hepatocytesProceedings of the National Academy of Sciences, 2007